GLUE (monterosatx.com) Enterprise Value-to-Revenue Coefficient

Official company branding of Monte Rosa Therapeutics Inc (GLUE)

The enterprise value-to-sales multiple for Monte Rosa Therapeutics (GLUE) reflects the revenue dynamics from licenses and partnerships with pharmaceutical leaders. An asset-light model, utilizing manufacturing outsourcing in the US and Switzerland, defines the cost structure, while a lack of pricing power due to early-stage testing leads to cash burn. The current value of this metric is 3321.06, which helps the analyst distinguish price anomalies from real growth drivers.

monterosatx.com (GLUE): EV/Sales Multiple from 11/23/2025 to 11/19/2026

Financial and market metric breakdowns for Monte Rosa Therapeutics, Inc. (GLUE)

- business market valuation indicators:
Fundamental company valuation:Monte Rosa Therapeutics GLUE
Product sample of monterosatx.com

Monte Rosa Therapeutics (GLUE) develops innovative protein degradation drugs using the QuEEN platform. The EV/Sales trend reflects the total enterprise value, including debt, relative to generated revenue. This multiple eliminates accounting distortions, demonstrating the company's actual margin of safety. High EV/Sales values confirm the potential of previously inaccessible therapeutic targets; however, such a valuation increases the risk of a correction should revenue growth rates slow.